Potential Mortality Reduction with Optimal Usage of Sacubitril/Valsartan Therapy for the Treatment of Heart Failure in Brazil

PARADIGM-HF, a phase III trial conducted in patients with heart failure with reduced ejection fraction (HFrEF), showed that sacubitril/valsartan, a first-in-class angiotensin receptor neprilysin inhibitor, provided incremental cardiovascular and overall survival benefit compared with enalapril. This analysis aims to quantify the number of all-cause deaths that potentially could be avoided with optimal usage of sacubitril/valsartan in the treatment of HFrEF in Brazil.
Source: Value in Health - Category: International Medicine & Public Health Authors: Source Type: research